{"entity":{"id":"nct07589530","kind":"trial","name":"Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors","aka":[],"tldr":"A phase 1/2 trial of EB-NK-301 and Fludarabine in advanced solid tumours, run by Beijing Biotech, now recruiting.","summary":"Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors. ClinicalTrials.gov record last updated 2026-05-15: recruiting. Enrollment is planned at 60 participants. Primary completion is estimated at 2027-02-14. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: EB-NK-301, Fludarabine. Registered primary measures: Incidence of dose-limiting toxicities (DLTs) (CTCAE v5.0); Incidence and severity of treatment-emergent adverse events (AEs); Recommended Phase 2 dose (RP2D) of EB-NK-301.","status":"recruiting","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT07589530","url":"https://clinicaltrials.gov/study/NCT07589530"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":["car-nk-macrophage"],"targets":["trop2"],"drugs":["eb-nk-301","fludarabine"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["ClinicalTrials.gov record last updated 2026-05-15: recruiting. Enrollment is planned at 60 participants. Primary completion is estimated at 2027-02-14. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications."],"nct":"NCT07589530","phase":"1/2","setting":"Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors","sponsor":"Beijing Biotech","participation":[{"nct":"NCT07589530","source":"https://clinicaltrials.gov/study/NCT07589530","fetchedAt":"2026-10-07T16:55:50.238Z","studySha256":"d05396de9d905ed6f2b12b7b93d1d663e305a8a3bbbccb3abc71daaef5cd922a","overallStatus":"RECRUITING","lastUpdatePosted":"2026-05-15","leadSponsor":"Beijing Biotech","collaboratorCount":0,"minimumAge":"18 Years","maximumAge":"75 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":60,"enrolmentType":"ESTIMATED","siteCount":1,"recruitingSiteCount":1,"countries":["China"]}],"started":"2026-03-02","startedType":"actual","enrolled":60,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07589530/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"technology":[{"id":"car-nk-macrophage","kind":"technology","name":"CAR-NK & CAR-macrophage","route":"/technologies/car-nk-macrophage/"}],"target":[{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}],"drug":[{"id":"eb-nk-301","kind":"drug","name":"EB-NK-301","route":"/drugs/eb-nk-301/"},{"id":"fludarabine","kind":"drug","name":"Fludarabine","route":"/drugs/fludarabine/"}]}}